Cargando…
Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication. However, a mechanism of removal of the incorporated dFdC is largely unknown. In this report, we dis...
Autores principales: | George, Joseph W., Bessho, Mika, Bessho, Tadayoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421022/ https://www.ncbi.nlm.nih.gov/pubmed/30941207 http://dx.doi.org/10.1155/2019/6357609 |
Ejemplares similares
-
Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction
por: Al-Mugotir, Mona, et al.
Publicado: (2021) -
Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation
por: Wang, Jiajia, et al.
Publicado: (2020) -
Protein phosphatase 1 and phosphatase 1 nuclear targeting subunit-dependent regulation of DNA-dependent protein kinase and non-homologous end joining
por: Zhu, Songli, et al.
Publicado: (2017) -
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2012) -
XPF expression and its relationship with the risk and prognosis of colorectal cancer
por: Hu, Huixin, et al.
Publicado: (2021)